Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 1, 2016, Pages 63-71

  Golabi, Pegah ^a   Sayiner, Mehmet ^a   Fazel, Yousef ^a   Koenig, Aaron ^a   Henry, Linda ^a   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Diagnosis; Fibrosis; NAFLD; NASH; Noninvasive methods; Screening

Indexed keywords

BIOLOGICAL MARKER;

ADVERSE OUTCOME; BARD SCORE; BIOCHEMISTRY; BREATH ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE MARKER; DISEASE SEVERITY; ELASTOGRAPHY; FATTY LIVER INDEX; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; NAFLD FIBROSIS SCORE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; BLOOD; COMPLICATION; LIVER CIRRHOSIS; MASS SCREENING; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

BIOMARKERS; BREATH TESTS; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MASS SCREENING; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84945207499     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1099433     Document Type: Review

References (71)

1. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475-485.
2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826.
3. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524-530 e1; quiz e60.
4. Otgonsuren M, Estep MJ, Hossain N, et al. A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol. 2014;29:2006-2013.
5. Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA. 2015;313:2263-2273.
6. WGO. World Gastroenterology Organisation Global Guidelines, Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. WGO Global Guidelines. 2012. Accessed from: Http://www.worldgastroenterology.org/assets/export/userfiles/2012-NASH%20and% 20NAFLD-Final-long.pdf.
7. Fleischman MW, Budoff M, Zeb I, et al. NAFLD prevalence differs among Hispanic subgroups: The Multi-Ethnic Study of Atherosclerosis. World J Gastroenterol. 2014;20:4987-4993.
8. Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis. Am J Gastroenterol. 2014;109:325-334.
9. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874-1882.
10. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liverrelated mortality in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-3023.
11. Hu KC, Wang HY, Liu SC, et al. Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol. 2014;20:7718-7729.
12. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
13. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129:113-121.
14. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-1253.
15. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136:1585-1592.
16. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
17. Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism. 2014;63:161-167.
18. Schuppan D, Schattenberg JM. Nonalcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(Suppl 1):68-76.
19. Ertle J, Dechene A, Sowa JP, et al. Nonalcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436-2443.
20. Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2012;2:135-144.
21. Jung KY, Cho SY, Kim HJ, et al. Nonalcoholic steatohepatitis associated with metabolic syndrome: Relationship to insulin resistance and liver histology. J Clin Gastroenterol. 2014;48:883-888.
22. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75:721-728.
23. Idilman IS, Keskin O, Celik A, et al. A comparison of liver fat content as determined by magnetic resonance imagingproton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol. doi:10.1177/0284185115580488 (2015) (Epub ahead of print).
24. Cowin GJ, Jonsson JR, Bauer JD, et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging. 2008;28:937-945.
25. Chen J, Talwalkar JA, Yin M, et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011;259:749-756.
26. Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y). 2012;8:605-607.
27. Roulot D, Costes JL, Buyck JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut. 2010;60:977-984.
28. Zhang E, Wartelle-Bladou C, Lepanto L, et al. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. doi:10.1007/s00330-015-3731-2 (2015) (Epub ahead of print).
29. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199-208.
30. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862-1871.
31. Liu H, Fu J, Hong R, et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: A systematic review & metaanalysis. PLoS One. 2015;10:e0127782.
32. Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness as a noninvasive method for diagnosis of nonalcoholic fatty liver disease. Hepatol Res. 2015;45:142-151.
33. Hines CD, Bley TA, Lindstrom MJ, et al. Repeatability of magnetic resonance elastography for quantification of hepatic stiffness. J Magn Reson Imaging. 2010;31:725-731.
34. Kim D, Kim WR, Talwalkar JA, et al. Advanced fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment with MR elastography. Radiology. 2013;268:411-419.
35. Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology. 2014;60:1920-1928.
36. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. PMID: 25911335. doi:10.1016/j.jhep.2015.04.006.
37. Barsic N, Lerotic I, Smircic-Duvnjak L, et al. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18:3945-3954.
38. Rossi E, Adams LA, Ching HL, et al. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. Clin Chem Lab Med. 2013;51:1107-1114.
39. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009;50:1072-1078.
40. Musso G, Gambino R, Cassader M, et al. Meta-analysis: Natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-649.
41. Yang M, Xu D, Liu Y, et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS One. 2015;10:e0131664.
42. Kamada Y, Akita M, Takeda Y, et al. Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS One. 2013;8: E66328.
43. Kamada Y, Fujii H, Sawai Y, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl. 2013;7:648-656.
44. Kamada Y, Ono M, Hyogo H, et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology. doi:10.1002/hep.28002 (2015) (Epub ahead of print).
45. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40.
46. Arora A, Sharma P. Non-invasive diagnosis of fibrosis in non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2012;2:145-155.
47. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455-460.
48. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59:1245-1251.
49. Adams LA, George J, Bugianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:1536-1543.
50. Costelloe SJ, Theocharidou E, Tsochatzis E, et al. Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology. Eur J Gastroenterol Hepatol. 2015;27:313-320.
51. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854.
52. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of nonalcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56:234-240.
53. Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.
54. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-36.
55. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with nonalcoholic fatty liver disease. Gut. 2010;59:1265-1269.
56. Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2015;35:1566-1573.
57. Wada T, Zeniya M. Background of the FIB-4 index in Japanese non-alcoholic fatty liver disease. Intern Med. 2015;54:127-132.
58. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
59. Carvalhana S, Leitao J, Alves AC, et al.How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: Correlation with ultrasound. Liver Int. 2014;34:e111-7.
60. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384.
61. Buzzetti E, Lombardi R, De Luca L, et al. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol. 2015;2015:343828.
62. Lee TH, Han SH, Yang JD, et al. Prediction of advanced fibrosis in nonalcoholic fatty liver disease: An enhanced model of BARD Score. Gut Liver. 2013;7:323-328.
63. Tapper EB, Krajewski K, Lai M, et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of nonalcoholic fatty liver disease. Gastroenterol Rep (Oxf). 2014;2:276-280.
64. Armuzzi A, Candelli M, Zocco MA, et al. Review article: Breath testing for human liver function assessment. Aliment Pharmacol Ther. 2002;16:1977-1996.
65. Tribonias G, Margariti E, Tiniakos D, et al. Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2014;48:59-65.
66. Verdam FJ, Dallinga JW, Driessen A, et al. Non-alcoholic steatohepatitis: A non-invasive diagnosis by analysis of exhaled breath. J Hepatol. 2013;58:543-548.
67. Park GJ, Wiseman E, George J, et al. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. J Gastroenterol Hepatol. 2011;26:1411-1416.
68. Gaidos JK, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int. 2008;28:650-658.
69. Gawrieh S, Knoedler DM, Saeian K, et al. Effects of interventions on intraand interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Pathol. 2011;15:19-24.
70. Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:9026-9037.
71. Agopian VG, Kaldas FM, Hong JC, et al. Liver transplantation for nonalcoholic steatohepatitis: The new epidemic. Ann Surg. 2012;256:624-633.